7
H index
5
i10 index
102
Citations
Mary K. Olson : Citation Profile
Tulane University | RESEARCH PRODUCTION: 15 Articles 1 Papers RESEARCH ACTIVITY:
MORE DETAILS IN: ABOUT THIS REPORT:
|
33 years (1992 - 2025). Relations with other researchers
Works with: Authors registered in RePEc who have co-authored more than one work in the last five years with Mary K. Olson. | Is cited by:
| Cites to:
|
Main data
Where Mary K. Olson has published?
| Journals with more than one article published | # docs |
|---|---|
| Journal of Economics & Management Strategy | 3 |
| The Journal of Law, Economics, and Organization | 3 |
| Journal of Health Economics | 2 |
Recent works citing Mary K. Olson (2025 and 2024)
| Year | Title of citing document |
|---|---|
| 2024 | Regulating ethical experimentation: Impacts of the breakthrough therapy designation on drug R&D. (2024). Hermosilla, Manuel. In: Journal of Health Economics. RePEc:eee:jhecon:v:94:y:2024:i:c:s0167629623001327. Full description at Econpapers || Download paper |
| 2024 | Do R&D tax credits impact pharmaceutical innovation? Evidence from a synthetic control approach. (2024). Jofre-Bonet, Mireia ; Oliver, Edward ; Kourouklis, Dimitrios. In: Research Policy. RePEc:eee:respol:v:53:y:2024:i:8:s0048733324001021. Full description at Econpapers || Download paper |
| 2024 | Cost benefit analysis and the FDA: measuring the costs and benefits of drug approval under the PDUFA I-II, 1998–2005. (2024). Decanio, Samuel. In: Journal of Regulatory Economics. RePEc:kap:regeco:v:66:y:2024:i:2:d:10.1007_s11149-024-09477-2. Full description at Econpapers || Download paper |
| 2024 | Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy. (2024). Boch, Tobias ; Michaeli, Thomas ; Albers, Sebastian. In: The European Journal of Health Economics. RePEc:spr:eujhec:v:25:y:2024:i:6:d:10.1007_s10198-023-01639-x. Full description at Econpapers || Download paper |
Works by Mary K. Olson:
| Year | Title | Type | Cited |
|---|---|---|---|
| 2025 | Reassessing the impact of health IT: Hidden costs and consequences of vendor heterogeneity In: Journal of Economics & Management Strategy. [Full Text][Citation analysis] | article | 0 |
| 1997 | Firm Characteristics and the Speed of FDA Approval In: Journal of Economics & Management Strategy. [Full Text][Citation analysis] | article | 15 |
| 2000 | Regulatory Reform and Bureaucratic Responsiveness to Firms: the Impact of User Fees in the FDA In: Journal of Economics & Management Strategy. [Full Text][Citation analysis] | article | 2 |
| 2004 | Are novel drugs more risky for patients than less novel drugs? In: Journal of Health Economics. [Full Text][Citation analysis] | article | 17 |
| 2008 | The risk we bear: The effects of review speed and industry user fees on new drug safety In: Journal of Health Economics. [Full Text][Citation analysis] | article | 15 |
| 1992 | Pharmaceutical Expenditure and Regulatory Policy in the NHS. In: Washington St. Louis - School of Business and Political Economy. [Citation analysis] | paper | 0 |
| 2013 | Eliminating the U.S. drug lag: Implications for drug safety In: Journal of Risk and Uncertainty. [Full Text][Citation analysis] | article | 2 |
| 1994 | Political Influence and Regulatory Policy: The 1984 Drug Legislation. In: Economic Inquiry. [Citation analysis] | article | 1 |
| 1995 | Regulatory Agency Discretion among Competing Industries: Inside the FDA. In: The Journal of Law, Economics, and Organization. [Citation analysis] | article | 11 |
| 1996 | Substitution in Regulatory Agencies: FDA Enforcement Alternatives. In: The Journal of Law, Economics, and Organization. [Citation analysis] | article | 8 |
| 1999 | Agency Rulemaking, Political Influences, Regulation, and Industry Compliance. In: The Journal of Law, Economics, and Organization. [Citation analysis] | article | 7 |
| 1995 | The Effects of UK Pharmaceutical Policy on Government Drug Expenditure: Cost Control and Incentives for R&D In: International Journal of the Economics of Business. [Full Text][Citation analysis] | article | 1 |
| 2018 | Examining Firm Responses to R&D Policy: An Analysis of Pediatric Exclusivity In: American Journal of Health Economics. [Full Text][Citation analysis] | article | 7 |
| 2018 | Examining Firm Responses to R&D Policy: An Analysis of Pediatric Exclusivity.(2018) In: American Journal of Health Economics. [Full Text][Citation analysis] This paper has nother version. Agregated cites: 7 | article | |
| 2002 | Pharmaceutical Policy Change and the Safety of New Drugs In: Journal of Law and Economics. [Full Text][Citation analysis] | article | 15 |
| 2021 | New clinical information and physician prescribing: How do pediatric labeling changes affect prescribing to children? In: Health Economics. [Full Text][Citation analysis] | article | 1 |
CitEc is a RePEc service, providing citation data for Economics since 2001. Last updated December, 22 2025. Contact: CitEc Team